Aeolus Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2016. For the quarter, the company reported contract revenues of $660,000 compared with $63,000 for the same period last year. Loss from operations was $872,000 compared with $784,000 for the same period last year. Net loss was $872,000 or $0.01 basic and diluted share compared with $784,000 or $0.01 basic and diluted per share for the same period last year. Higher revenue in 2016 reflects the timing of the initiation of program items and revenue recognition under accounting rules. For the nine months, the company reported contract revenue of $1,530,000 compared with $2,177,000 for the same period last year. Loss from operations was $2,250,000 compared with $2,194,000 for the same period last year. Net loss was $2,535,000 or $0.03 basic and diluted share compared with $2,194,000 or $0.02 basic and diluted share for the same period last year. Net cash used in operating activities was $2,508,000 compared with $1,121,000 for the same period last year. The increase in net loss during the nine months ended June 30, 2016 was primarily attributable to a $2,486,000 non-cash expense related to a deemed dividend for the Company's Series C Preferred Stock. The net operating loss for the nine months ended June 30, 2016 was $2,250,000 or $0.02 per share. Lower revenue in 2016 reflects the timing of the initiation of program items and revenue recognition under accounting rules.